M8046

Mifepristone

≥98%

• Sinônimo(s): 11β-(4-Dimethyl­amino)­phenyl-17β-hydroxy-17-(1-propynyl)­estra-4,9-dien-3-one, RU-38486, RU-486
• Fórmula empírica (Notação de Hill): C₂₉H₃₅NO₂
• Número CAS: 84371-65-3
• Peso molecular: 429.59
• Número MDL: MFCD00867226
• Código UNSPSC: 51111800
• ID de substância PubChem: 24278572
• NACRES: NA.77

Propriedades

• fonte biológica: synthetic (organic)
• esterilidade: non-sterile
• Ensaio: ≥98%
• forma: powder
• técnica(s): inhibition assay: suitable
• solubilidade: ethanol: 50 mg/mL, clear, greenish-yellow
• originador: Danco Laboratories
• Condições de expedição: ambient
• temperatura de armazenamento: 2-8°C
• cadeia de caracteres SMILES: [H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]4(C)[C@@]2([H])CC[C@@]4(O)C#CC)c5ccc(cc5)N(C)C
• InChI: 1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
• chave InChI: VKHAHZOOUSRJNA-GCNJZUOMSA-N
• Informações sobre genes: human ... AR(367) , ESR1(2099) , ESR2(2100) , HTR1A(3350) , HTR1B(3351) , HTR1D(3352) , HTR1E(3354) , HTR1F(3355) , HTR2A(3356) , HTR2B(3357) , HTR2C(3358) , HTR3A(3359) , HTR3B(9177) , HTR3C(170572) , HTR3D(200909) , HTR3E(285242) , HTR4(3360) , HTR5A(3361) , HTR5B(645694) , HTR6(3362) , HTR7(3363) , NR3C1(2908) , NR3C2(4306) , PGR(5241) ; mouse ... Nr3c1(14815) ; rat ... Nr3c1(24413) , Tat(24813)

Descrição

Descrição geral

Mifepristone, a synthetic steroid, can be utilized for the management of Cushing′s syndrome and uterine leiomyomas. At low doses, it selectively antagonizes progesterone by binding to the intracellular progesterone receptor. At higher doses, mifepristone blocks cortisol at the glucocorticoid receptor, affecting the hypothalamic-pituitary-adrenal axis and leading to increased circulating cortisol, thereby controlling hyperglycemia in some patients. Additionally, mifepristone has a higher affinity for the glucocorticoid II receptor than for the glucocorticoid I receptor. In cases of pregnancy termination, mifepristone disrupts progesterone.

Aplicação

Mifepristone has been used:

• to induce damage against the proliferative and secretory phase of endometrial stromal cells
• to establish a preterm birth (PTB) mice model in order to study the difference in cervical ripening mechanism between term and PTBs
• to activate geneswitch gal4 in flies
• to study the effects of sex steroids on prostaglandin secretion

Ações bioquímicas/fisiológicas

Therefore, mifepristone is considered to be a potent abortifacient. It is also known to inhibit human chorionic gonadotropin. Mifepristone results in decidual necrosis.

Mifepristone (RU-486) has activity as both a progesterone receptor antagonist and a glucocorticoid receptor antagonist.

Características e benefícios

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Danco Laboratories. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informações de segurança

• Pictogramas: GHS08
• Palavra indicadora: Danger
• Frases de perigo: H360
• Declarações de precaução: P201 - P308 + P313
• Classificações de perigo: Repr. 1B
• Código de classe de armazenamento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable
• Equipamento de proteção individual: Eyeshields, Gloves, type P3 (EN 143) respirator cartridges